In a report released today, Jason Gerberry from Bank of America Securities maintained a Hold rating on Alkermes (ALKS – Research Report), with ...

Alkermes plc (NASDAQ:ALKS – Get Free Report) has been assigned an average rating of “Moderate Buy” from the thirteen research firms that are covering the stock, MarketBeat.com reports. Four investment ...

Cibc World Markets Corp bought a new stake in Alkermes plc (NASDAQ:ALKS – Free Report) in the fourth quarter, according to ...

The 6th GxP Cloud Compliance Summit is uniting Life Science companies to manage data security risks, validate internal and ...

Alkermes (ALKS) reported earnings 30 days ... with Rinvoq and Skyrizi delivering especially strong sales growth. Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92 ...

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

The major stock indexes found energy in the final minutes of trading and closed in positive territory on stock market today.

Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...

BofA raised the firm’s price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm’s higher target ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...